Bioniche will file BLA with the US FDA, seeking approval for the commercialization of MCNA based on existing clinical data; Target filing date: Q1/2015 . Near term revenue opportunity in the U.S Potential for marketing approval as early as end of 2015/early 2016 .Exploring potential for US listing .
Pivotal phase 3 study (completed) shows it can delay (or prevent) need for cystectomy (bladder removal) in 25% of patients with high-risk non-muscle invasive bladder cancer (NMIBC) who failed first line BCG treatment
Supported by strong intellectual property coverage •Patent term expiration: 2031 •Automatic 12 year market exclusivity for novel biologic in US
Of all cancers, bladder cancer has the greatest lifetime treatment cost per patient diagnosed (US, 2010) $230,000 . 80,000 new cases/year in North America .
Potential for peak U.S. sales of $200M plus .Comparable or greater market opportunity ex-US
•NMIBC BCG-failure population only •50% market penetration •$3,000 per dose
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.